Property Summary

NCBI Gene PubMed Count 17
PubMed Score 14.45
PubTator Score 10.62

Knowledge Summary


No data available


  Disease Sources (2)

Disease Target Count P-value
lung carcinoma 2844 1.52805857761257E-34
psoriasis 6685 3.30459238347004E-17
non-small cell lung cancer 2798 2.03253871700214E-14
lung cancer 4473 9.64612267468923E-8
atypical teratoid / rhabdoid tumor 4369 5.39422527478209E-7
oligodendroglioma 2849 2.99588255873756E-6
pancreatic cancer 2300 1.12225863466908E-5
colon cancer 1475 2.83570273076772E-5
group 4 medulloblastoma 1875 5.66326239731491E-5
intraductal papillary-mucinous neoplasm (IPMN) 3289 2.10823701829811E-4
glioblastoma 5572 0.00114797149967562
pediatric high grade glioma 2712 0.00146434922261681
pilocytic astrocytoma 3086 0.00159376457562469
astrocytic glioma 2241 0.00485475674907454
primary pancreatic ductal adenocarcinoma 1271 0.00790157791820557
non diabetic and post-ischemic heart failure 200 0.00801446593217243
ovarian cancer 8492 0.00995164343296943
type II diabetes mellitus and post-ischemic heart failure 89 0.0104560263681864
intraductal papillary-mucinous adenoma (IPMA) 2956 0.013488424092294
intraductal papillary-mucinous carcinoma (IPMC) 2988 0.0145686666016154
invasive ductal carcinoma 2950 0.0238731919237978
medulloblastoma, large-cell 6234 0.0262515786323336
primitive neuroectodermal tumor 3031 0.0288416822639325
ependymoma 2514 0.0309927880424062
Breast cancer 3099 0.0327288051901123
Disease Target Count Z-score Confidence
Benign meningioma 6 3.357 1.7



Accession Q8TAP4 B4DG90 B4DH35 Q58A66 Q58A67 Q8N974 Q9UDD5 LMO-3
Symbols RBTN3


  Ortholog (8)

Gene RIF (7)

25829251 MiR-101 decreased the expression of LMO3 by reversing the methylation status of the LMO3 promoter and by inhibiting the presence of the methylation-related histones H3K4me2 and H3K27me3 and increasing the presence of H3K9me3 and H4K20me3 on the promoter.
23823477 LMO3 as a regulator of human adipogenesis and could contribute a mechanism resulting in visceral-fat accumulation in obesity due to excess glucocorticoids.
23322301 suggest that LMO3 is a transcriptional signal transducer in NKX2-1-amplified lung adenocarcinomas
22011669 We confirmed that the expression of LMO3 in squamous cell carcinoma is regulated by DNA methylation of its specific promoter region.
21573214 The present results suggest that a transcriptional complex of LMO3 and HEN2 may contribute to the genesis and malignant phenotype of neuroblastoma by inhibiting HES1 which suppresses the transactivation of Mash1.
19995558 LMO3 acts as a co-repressor of p53, suppressing p53-dependent transcriptional regulation without inhibition of its DNA-binding activity.
15930276 The deregulated expression of neuronal-specific LMO3 and HEN2 contributes to the genesis and progression of human neuroblastoma in a lineage-specific manner.

AA Sequence

APQVR                                                                     141 - 145

Text Mined References (18)

PMID Year Title
25829251 2015 MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells.
25416956 2014 A proteome-scale map of the human interactome network.
24379077 2014 LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins.
23823477 2013 Human but not mouse adipogenesis is critically dependent on LMO3.
23322301 2013 Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.
22011669 2012 Genome-wide analysis of DNA methylation and the gene expression change in lung cancer.
21573214 2011 Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1.
19995558 2010 LMO3 interacts with p53 and inhibits its transcriptional activity.
16713569 2006 A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.
16541075 2006 The finished DNA sequence of human chromosome 12.